PMC:7796052 / 6173-6530 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"183","span":{"begin":72,"end":80},"obj":"Disease"},{"id":"195","span":{"begin":169,"end":179},"obj":"Chemical"}],"attributes":[{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" for its repurposing as a therapeutic agent for the treatment of severe Covid-19.\n\n2. Results and Discussion\nIn order to have a preliminary insight into the affinity of ralixofene towards the bradykinin receptors, the compound was first tested at 20 µM for its capacity to displace a reference ligand from B1 and B2, respectively. Specifically, desArg10-kal"}

{"project":"LitCovid-sentences","denotations":[{"id":"T41","span":{"begin":83,"end":85},"obj":"Sentence"},{"id":"T42","span":{"begin":86,"end":108},"obj":"Sentence"},{"id":"T43","span":{"begin":109,"end":330},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" for its repurposing as a therapeutic agent for the treatment of severe Covid-19.\n\n2. Results and Discussion\nIn order to have a preliminary insight into the affinity of ralixofene towards the bradykinin receptors, the compound was first tested at 20 µM for its capacity to displace a reference ligand from B1 and B2, respectively. Specifically, desArg10-kal"}